Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy (CERTAIN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01239004 |
Recruitment Status :
Completed
First Posted : November 11, 2010
Last Update Posted : January 6, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dyslipidemia Hyperlipidemia Hyperglycemia | Drug: Placebo Drug: Colesevelam | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 140 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia |
Study Start Date : | November 2010 |
Actual Primary Completion Date : | August 2011 |
Actual Study Completion Date : | August 2011 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo |
Drug: Placebo
6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks |
Experimental: Colesevelam |
Drug: Colesevelam
6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
Other Name: Welchol |
- Low-density lipoprotein cholesterol (LDL-C) [ Time Frame: 12 weeks ]The primary efficacy endpoint will be the mean percent change from baseline (average of Weeks -1 and 1) to end-of-treatment (average of Weeks 10 and 12) in LDL-C. It will be measured as part of the fasting lipid panel at Visits 1, 2, 3, 7, and 8/ET (Weeks -6 to -2, -1, 1, 10 and 12/ET).
- Fasting Plasma Glucose (FPG) [ Time Frame: 12 weeks ]The principal secondary efficacy endpoint is the mean change in FPG from baseline (average of Weeks -1 and 1) to end-of-treatment (average of Weeks 10 and 12).
- NMR Lipid subfractions and lipoprotein-IR score [ Time Frame: 12 weeks ]A secondary efficacy endpoint is the mean change from baseline (Week 1) to end-of-treatment(Week 12) in NMR Lipid subfractions and lipoprotein-IR score.
- Hemoglobin A1C (HbA1C) [ Time Frame: 12 weeks ]A secondary efficacy endpoint is the mean change from baseline (Week 1) to end-of-treatment(Week 12) in HbA1c.
- Fructosamine [ Time Frame: 12 weeks ]A secondary efficacy endpoint is the mean change from baseline (average of Weeks -1 and 1) to end-of-treatment (average of Weeks 10 and 12) in fructosamine.
- High sensitivity c-reactive protein (hs-CRP) [ Time Frame: 12 weeks ]A secondary efficacy endpoint is the mean change from baseline (average of Weeks -1 and 1) to end-of-treatment (average of Weeks 10 and 12) in hs-CRP.
- Niacin-related flushing [ Time Frame: 12 weeks ]Niacin-associated flushing will be measured using a visual analog scale (VAS)at Weeks 2,4,6,10 and 12.
- Homeostasis model assessment of insulin resistance (HOMA-IR) score [ Time Frame: 12 weeks ]A secondary efficacy endpoint is the mean change from baseline (Week 1) to end-of-treatment (Week 12) in HOMA-IR.
- High-density lipoprotein cholesterol (HDL-C) [ Time Frame: 12 weeks ]A secondary endpoint is the mean percent change from baseline (average of Weeks -1 and 1) to end-of-treatment (average of Weeks 10 and 12) in HDL-C.
- Non-high-density lipoprotein cholesterol (non-HDL-C) [ Time Frame: 12 weeks ]A secondary endpoint is the mean percent change from baseline (average of Weeks -1 and 1) to end-of-treatment (average of Weeks 10 and 12) in non-HDL-C.
- Total Cholesterol (TC) [ Time Frame: 12 weeks ]A secondary endpoint is the mean percent change from baseline (average of Weeks -1 and 1) to end-of-treatment (average of Weeks 10 and 12) in TC.
- Triglycerides (TG) [ Time Frame: 12 weeks ]A secondary endpoint is the mean percent change from baseline (average of Weeks -1 and 1) to end-of-treatment (average of Weeks 10 and 12) in TG.
- Fasting Insulin [ Time Frame: 12 weeks ]A secondary efficacy endpoint is the mean change from baseline (Week 1) to end-of-treatment (Week 12) in fasting insulin.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men and women ≥ 18 years of age.
- Non-HDL-C ≥100 mg/dL and ≤220 mg/dL at Visits 1 and 2.
- FPG ≥90 mg/dL and ≤145 mg/dL, at Visits 1 and 2.
- HDL-C <60 mg/dL at Visits 1 and 2, regardless of gender.
- Untreated dyslipidemia, or statin treatment only with equipotency to atorvastatin ≤40 mg daily for at least 12 weeks prior to Screening Visit 1 and without change or initiation prior to randomization
Exclusion Criteria:
- Known intolerance to niacin or bile acid-sequestering drugs or aspirin.
- Any contraindication to a study medication (niacin, aspirin or colesevelam).
- History of dysphagia, swallowing disorders or intestinal motility disorders.
- History of pancreatitis.
- Fasting TG >500 mg/dL at Visits 1 and 2
- Currently taking medication for diabetes mellitus, Type 1 or 2,or currently taking glucose-lowering drugs (e.g. metformin) for any other indication.
- Currently taking drugs that may affect glycemic and/or lipid control (e.g., beta-blockers, etc.) if started within the 12 weeks prior to Visit 1, or prior to randomization. This does not apply to dietary supplements.).
- Body mass index (BMI) >40 kg/m2.
- History of acute myocardial infarction, unstable angina, transient ischemic attacks, stroke or revascularization procedure within the 3 months prior to Visit 1 or prior to randomization.
- Use of prescription strength niacin, bile acid sequestrants, fibrates or omega-3 fatty acids within 8 weeks prior to Visit 1 or prior to randomization. This does not apply to dietary supplements.
- Unwilling to abstain, during the study, from weight-loss drugs (including over-the-counter) or weight-loss programs during the study.
- Current use, or intended use during the study, of cyclic hormones (e.g., oral or vaginal contraceptives and estrogen replacement therapy).
- Females who are pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential not using an acceptable method of contraception. Acceptable methods include intrauterine device, cervical diaphragm plus spermicide, female condom plus spermicide, or partner's use of condoms plus spermicide. Partner's vasectomy only or use of condoms or spermicide only are not considered acceptable forms of birth control.
- Current use, or intended use during the study of cyclosporine.
- Recent history (past 12 months) of illicit drug use or excessive ethanol use. Excessive ethanol use will be defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor).
- Exposure to any investigational agent within 30 days prior to Visit 1, and prior to randomization.
- Individual has a condition the Investigator believes would interfere with his ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01239004
United States, Illinois | |
Radiant Research | |
Chicago, Illinois, United States | |
United States, Kansas | |
Kansas City, Kansas, United States | |
United States, Minnesota | |
Minneapolis, Minnesota, United States | |
United States, Missouri | |
St Louis, Missouri, United States |
Principal Investigator: | Michael H Davidson, MD, FACC | Executive Medical Director, Radiant Research |
Responsible Party: | Radiant Research |
ClinicalTrials.gov Identifier: | NCT01239004 |
Other Study ID Numbers: |
Welchol-Niaspan 001 |
First Posted: | November 11, 2010 Key Record Dates |
Last Update Posted: | January 6, 2012 |
Last Verified: | January 2012 |
dyslipidemia hyperlipidemia hyperglycemia impaired fasting glucose |
Dyslipidemias Hyperglycemia Hyperlipidemias Hyperlipoproteinemias Lipid Metabolism Disorders Metabolic Diseases Glucose Metabolism Disorders |
Colesevelam Hydrochloride Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents |